Panelists Grapple With Unclear Data At Paclitaxel Meeting
Executive Summary
A two-day US FDA advisory committee meeting this week yielded plenty of discussion about the apparent mortality risk tied to paclitaxel-coated balloons and stents, but few definitive conclusions.
You may also be interested in...
T2Bacteria Panel Wins CMS Approval For New Tech Add-On Payment
The US Medicare agency approved a new technology add-on payment (NTAP) for T2 Biosystems’ blood test, the T2Bacteria panel, for the fiscal year that will begin on 1 October.
FDA Announces More Actions On Drug-Coated Devices
The US FDA’s latest update on the safety of paclitaxel-coated balloons and stents urges additional clinical trials. The agency also plans updates to device labeling and clinical trial informed consent documents that will reflect evidence that the devices may pose a mortality risk.
Boston Scientific Delivers Q2 Sales Growth Across Its Product Lines
Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.